Kondo Kazunari, Ishii Yoshiyuki, Ochi Hiroyuki, Matsumoto Tamae, Yoshikawa Hiroyuki, Kanda Tadahito
Center for Pathogen Genomics, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan.
Virology. 2007 Feb 20;358(2):266-72. doi: 10.1016/j.virol.2006.08.037. Epub 2006 Sep 28.
Neutralizing antibody against human papillomavirus (HPV) minor capsid protein L2 can cross-neutralize different HPV genotypes in vitro. To identify the segments containing the cross-neutralization epitopes of HPV16 L2, we characterized antisera obtained by immunizing two rabbits with each of the ten synthetic peptides of 14 to 20 amino acids (aa) long, which represents a part of the HPV16 L2 sequence from aa 14 to 144. The antisera against the peptides within the region from aa 18 to 144 efficiently bound to HPV16 L1/L2-capsids and neutralized HPV16 pseudovirions, indicating that the region is displayed on the surface of the capsids and contains several neutralization epitopes. Antiserum against the peptide from aa 18 to 38 (anti-P18/38) cross-neutralized HPV18. Anti-P56/75 cross-neutralized HPV18, 31, and 58. Anti-P61/75 and anti-P64/81 cross-neutralized HPV18 and 58. Anti-P96/115 and the antiserum induced by a mutant P96/115 (S and T at aa 101 and 112 were replaced with L and S, respectively) cross-neutralized HPV31 and 58. The mixture of equal volumes of three antisera, anti-P18/38, anti-P56/75, and anti-mutant P96/115, neutralized HPV16, 18, 31, and 58 more efficiently than anti-P56/75 alone, suggesting that there is a synergistic effect of antibodies on the cross-neutralization. The cross-neutralization appears to be correlated with conserved aa sequences among HPV types. The data in this study provide a basis for designing vaccine antigens effective against a broader spectrum of the high-risk HPVs.
抗人乳头瘤病毒(HPV)次要衣壳蛋白L2的中和抗体在体外可交叉中和不同的HPV基因型。为了鉴定包含HPV16 L2交叉中和表位的片段,我们对两只兔子分别用10种长度为14至20个氨基酸(aa)的合成肽进行免疫,得到抗血清,这些肽代表HPV16 L2序列中从aa14至144的一部分。针对aa18至144区域内肽段的抗血清能有效结合HPV16 L1/L2衣壳并中和HPV16假病毒,表明该区域位于衣壳表面并包含多个中和表位。针对aa18至38肽段的抗血清(抗-P18/38)可交叉中和HPV18。抗-P56/75可交叉中和HPV18、31和58。抗-P61/75和抗-P64/81可交叉中和HPV18和58。抗-P96/115以及由突变型P96/115(aa101和112处的S和T分别替换为L和S)诱导产生的抗血清可交叉中和HPV31和58。等体积的抗-P18/38、抗-P56/75和抗突变型P96/115三种抗血清混合物比单独使用抗-P56/75更有效地中和了HPV16、18、31和58,表明抗体在交叉中和中存在协同作用。交叉中和似乎与HPV各型之间保守的氨基酸序列相关。本研究中的数据为设计能有效对抗更广泛高危HPV谱的疫苗抗原提供了依据。